title: Iralukast Novartis AG.
abstract: Iralukast is an LTD4 and LTE4 antagonist under development by Novartis and in phase II clinical trials as a potential treatment for asthma [244117], [177071]. In a double-blind, placebo-controlled trial in 16 patients with mild to moderate asthma, a single 1.5 mg inhaled dose of iralukast reduced the incidence of exercise-induced bronchiospasm and was well-tolerated [272161]. Novartis has an agreement with Rhone-Poulenc Rorer to use its Ultrahaler delivery system for iralukast and phase II trials are underway [220836]. The agreement also involves the development of further related compounds and delivery systems.
authors.affiliation: Pulmonary Research Laboratory, 123-3440 West Broadway, Vancouver, V6R 4R2, Canada. Abramley@prl.pulmonary.ubc.ca
authors.forename: A
authors.initials: A
authors.lastname: Bramley